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Objectives: In randomized controlled trials, differences in prognostic factors 
– whether statistically significant or not – contribute to absolute differences in 
outcomes. Absolute differences are at the heart of economic evaluation. Economic 
modelling may help increase precision of incremental differences, despite ran-
domization. The objective of the present study was to describe the effect of 
economic modelling techniques on the magnitude and precision of economic 
and decision outcomes using a RCT-based economic evaluation. MethOds: An 
economic evaluation was conducted alongside a RCT (n= 350) in diagnostic inter-
ventional cardiology. Raw unadjusted total costs and QALYs were assembled at 
the individual level using resource use and EQ5D responses. For economic mod-
elling, outcomes were then conditioned according to the diagnosis and fit with 
generalized linear models, adjusting for baseline characteristics. Total costs and 
QALYs were then estimated using marginal prediction with the fitted models. 
Family and link functions were selected using the Modified Park’s and Pregibon 
Link test, respectively. Uncertainty in GLM coefficients, unit cost parameters 
and sampling were incorporated using bootstrapping and Monte Carlo meth-
ods. Results: The magnitude and direction of incremental costs were compa-
rable between the raw vs. modelled results (-£132 vs. -£204). However, precision 
increased considerably; the 95%CI reduced by 44% ([-£1772 to £817] vs. [-£1437 to 
£30]). Incremental QALYs also showed comparable magnitudes (0.013 vs -0.005), 
though the direction reversed, albeit by a non-important magnitude. As well, the 
95%CI of incremental QALYs reduced by 83% ([-0.033 to 0.060] vs. [-0.015 to 0.001]). 
Reduction in joint incremental cost-effect uncertainty was also apparent upon 
visual inspection of the cost-effectiveness plane. Decision (cost-effectiveness) 
uncertainty was comparable across the common willingness-to-pay thresholds 
(~70% at £0-£30,000/QALY). cOnclusiOns: Economic modelling can increase pre-
cision in economic outcomes and reduce uncertainty in decision making, support-
ing the results and decision arising from a raw unadjusted economic evaluation 
alongside a RCT.
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Objectives: Economic evaluations of competing interventions often estimate 
mean overall survival (OS) as a measure of intervention effect. New treatments 
offer some patients the possibility of being “cured” of their disease, in that they 
become long-term survivors whose risk of death is the same as a disease-free per-
son. Grouping cured and non-cured patients together and reporting one mean value 
for OS may provide a biased assessment of a therapy that cures a proportion of 
patients. In this study, we compared standard survival analysis versus an approach 
that accounts for the fraction of patients cured. MethOds: We used clinical trial 
data from advanced melanoma patients treated with ipilimumab (n= 137) versus 
gp100 (n= 136) and applied statistical methodology for mixture cure models. We used 
logistic regression to model the probability that a patient was cured and a Weibull 
regression model to estimate the excess mortality for non-cured patients. Both 
cured and non-cured patients were subject to background mortality not related to 
cancer; we calculated this using age- and gender-matched mortality data from US 
Social Security life tables. Results: Ignoring a cured proportion, ipilimumab had 
an estimated mean OS that was 8 months longer than gp100. Cure model analy-
sis showed that the proportion of cured patients drove this difference, with 20% 
cured on ipilimumab compared to 6% with gp100. The mean OS among non-cured 
patients was 5 months on ipilimumab versus 4 months on gp100. The mean OS 
among cured patients was 26 years on both arms. After adjusting for covariates, 
ipilimumab had an improved cure proportion compared to gp100 (OR= 2.01, 95% CI 
(1.00, 4.06)), but there were no significant differences in survival among non-cured 
patients (HR= 1.05, 95% CI (0.80, 1.38)). cOnclusiOns: This analysis supports using 
cure modeling in health economic evaluation in advanced melanoma, since it may 
reduce bias in OS estimates.
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Objectives: Methodologies and information systems associated with health 
intervention costs in Canada have evolved since the Guidance Document for the 
Costing Process was published in 1996. This document was produced to assist 
researchers undertaking economic studies of health interventions in Canada. To 
ensure this document is useful to researchers the Canadian Agency for Drugs 
and Technologies in Health (CADTH) is undertaking a major update of the docu-
ment. This presentation will provide an overview of the key changes to the 
document, based on the availability of new information sources and methodolo-
gies. MethOds: A literature review of Canadian economic evaluations published 
between 2011 to 2014 was conducted by CADTH to understand how cost infor-
mation is currently being used by researchers. In addition, CADTH conducted a 
scan of the various costing and resource use methodologies used in health care 
in Canada, and undertook discussions with researchers in health costing. Based 
on the information obtained, required revisions and additions to the Guidance 
Document were identified. Results: The updated Guidance Document con-
sists of eight sections: Pharmaceuticals, Physician Services, Hospital Services, 
Diagnostic and Investigational Services, Non-Physician Professional Services, 
Community Based Services, Informal Caregiver Costs, and Other Information. 
These categories give way to targeted subsections, for which, detailed descrip-
tions of cost components are provided, along with relevant data sources and 
guidance as to how and when researchers can apply the data. Key additions to 
this update include: the inclusion of newer methodologies (e.g., CMG+ costing, 
thresholds for reimbursement decisions, we describe a model for ensuring that 
opportunity cost is appropriately captured in the willingness-to-pay value. We 
then show how the modified model would impact upon coverage decisions which 
include an ‘end-of-life premium’. Results: We identify four broad categories of 
value premia. We characterise the importance of locating opportunity cost factors 
(including price and budget impact) outside the value framework. We then describe 
a structural process for ensuring that the value framework is applied equally to the 
identified beneficiaries of a technology and the frequently unidentified individuals 
who will bear the opportunity cost, in order to promote horizontal equity in HTA 
processes. Finally, we show how the conventional approach to incorporating value 
premia, such as the ‘end-of-life premium’, promotes inefficient and inequitable 
resource allocation decisions. cOnclusiOns: The conventional HTA model does 
not adequately reflect the social value of health care. However, naïve modifications 
to the cost-effectiveness threshold lead to both inefficient and inequitable resource 
allocation decisions. It is important that modified value frameworks are applied 
equally to the identified beneficiaries of a technology and those individuals who 
bear the opportunity cost.
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Objectives: The U.S. Agency for Healthcare Research and Quality (AHRQ) solicited 
the development of guidance for modeling and simulation studies conducted in the 
context of health technology assessment. MethOds: We updated and expanded 
existing systematic reviews of recommendations for the conduct and reporting 
of modeling and simulation studies in healthcare. We also solicited input from a 
multidisciplinary team of clinical, policy, and decision analysis experts. The Results 
of the systematic review were then discussed in person with a panel of 28 stake-
holders including patient representatives, providers and purchasers of care, payers, 
policy makers, and principal investigators. Stakeholders commented on existing 
recommendations and identified gaps, limitations, and areas for elaboration. We 
subsequently reviewed the websites of 126 health technology assessment organiza-
tions that provide guidance on the conduct and reporting of decision and simula-
tion models. We sought additional input from senior researchers with experience 
in modeling and simulation within AHRQ and its Evidence-based Practice Centers, 
and from external reviewers. Results: We developed principles and good practice 
recommendations for modeling and simulation studies conducted to enhance and 
contextualize the findings of systematic reviews. The guidance applies to struc-
tural mathematical models and simulation experiments based on such models. 
The recommendations address model identification, estimation, and evaluation, 
as well as the use of sensitivity, stability, and uncertainty analyses throughout 
model development and use. Recommendations are organized by whether they 
pertain to the model conceptualization and structure, data, consistency, or the 
interpretation and reporting of Results. We provide the rationale for each recom-
mendation, with supporting evidence or, when adequate evidence was lacking, 
best judgment. cOnclusiOns: We present systematically developed guidance for 
modeling and simulation in the context of health technology assessment. We are 
hopeful that this work will contribute to increased use of modeling and simulation 
in conjunction with systematic reviews.
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Objectives: To explain the relevance of and provide guidance for using a new cost 
metric, the National Average Drug Acquisition Cost (NADAC) for US based economic 
evaluations. The key feature of NADAC is that a single cost is reported for a unit of 
all pharmaceutically equivalent drugs. The cost is an average of the per unit cost 
paid by the current month’s national sample of retail pharmacies. MethOds: We 
propose a costing procedure and provide a detailed overview of costing for five 
diverse drugs and compare estimates to AWP, the current metric used as an estimate 
for acquisition cost. With data from 2014 and enumerated specific National Drug 
Codes (NDC) included in each estimate, we used the July cost as the base-case and 
the range observed over the year as a measure of uncertainty. For AWP we used its 
value on July 1. To eliminate the impact of obsolete NDCs we only considered the 
AWPs of NDCs that had an associated NADAC in 2014. The base-case was estimated 
as the average of AWP across equivalent NDCs and the range was the low and high 
AWP. Results: In one example, 500mg cephalexin had a NADAC of $0.09662 in July. 
This cost was based on 22 NDCs and was updated 11 times throughout the year. The 
range was [$0.08877, $0.12138] per unit. By contrast the distribution of AWPs for the 
same 22 NDCs had an average of $1.35606 and range of [$1.2259, $1.376]. In other 
drugs the ratio of NADAC and AWP ranged from 7-89%. cOnclusiOns: NADAC 
has limitations, but appears to provide a better estimate of true drug acquisition 
cost than AWP. Given the wide discrepancy observed between NADAC and AWP it 
appears using AWP, even discounted, may introduce bias in economic evaluations.
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